Eli Lilly (LLY) is expected to report Q2 earnings before the market open on Wednesday, July 25 with a conference call scheduled for 9:00 am ET.
Analysts are looking for EPS of 77c on revenue of $5.58B. The consensus range is 69c-81c for EPS and $5.46B-$5.72B for revenue, according to First Call. In April, the drug giant raised its FY12 EPS view to $3.15-$3.30, despite the dramatic drop in Zyprexa revenue in Q1. Zyprexa lost its patent protection in late 2011. Positives for the quarter may be seen coming from its animal health division. Also, drug sales in Cymbalta and Almita -- which were up in Q1 -- should help top-line results. Negatives can be seen coming from a reduction in Zyprexa sales and austerity measures in Europe. Eli Lilly's stock is down 4.4% today ahead of the company's Q2 earnings report.